Summary
Metabolically normal obesity (MNO) affects 30-50% of obese individuals, challenging traditional views. Adipose tissue distribution and function are key to understanding this metabolic health discrepancy in obesity.
Area of Science:
- Endocrinology
- Metabolic Health
- Obesity Medicine
Context:
- Significant overlap exists between obesity and metabolic health.
- 30-50% of obese individuals exhibit metabolically normal phenotypes.
- Metabolic abnormalities are also prevalent in non-obese populations.
Purpose:
- To characterize metabolically healthy obese (MHO) patients.
- To elucidate pathophysiological mechanisms underlying MHO.
- To assess cardiovascular risk and therapeutic strategies for MHO.
Summary:
- Metabolically normal obesity (MNO) is characterized by specific clinical and biological features.
- Adipose tissue distribution and function are critical determinants of metabolic health in obesity.
- This review analyzes the prognosis, particularly cardiovascular risk, and therapeutic options for MHO individuals.
Impact:
- Provides insights into the heterogeneity of obesity and metabolic health.
- Highlights the importance of adipose tissue depots in metabolic regulation.
- Informs clinical management and therapeutic approaches for obese patients with varying metabolic profiles.
More Related Videos
06:16White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
Published on: September 9, 2025
06:57Determining Basal Energy Expenditure and the Capacity of Thermogenic Adipocytes to Expend Energy in Obese Mice
Published on: November 11, 2021
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:18Metabolic States of the Body: The Postabsorptive State
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
01:24Metabolic States of the Body: Fasting and Starvation
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...